Literature DB >> 15939251

Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy.

Marianne Skov1, Karen McKay, Christian Koch, Peter J Cooper.   

Abstract

BACKGROUND: Lower airway colonisation with Aspergillus fumigatus and the complicating hypersensitivity reaction allergic bronchopulmonary aspergillosis (ABPA) is well recognised in patients with cystic fibrosis (CF). There is a wide range in reported prevalence of ABPA in CF. Differences in predisposing factors such as atopy and climatic humidity, but also differences in reporting may in part explain this observation. In the Australian population there is a high frequency of atopy and the climate is relatively humid. PATIENTS AND METHODS: Children and adolescents with CF (n = 277) from the CF Clinic, Children's Hospital at Westmead, Sydney, Australia were included in a retrospectively conducted study of Aspergillus colonisation and ABPA (1998-2003).
RESULTS: The prevalence of Aspergillus colonised patients increased significantly from 7.4% in 1998 to 18.8% in 2002. No seasonal variation in initial positive Aspergillus culture or in humidity was observed. A total of 13 patients (4.7%) were diagnosed with ABPA over the study period, with a significant increase in prevalence from 0.3% in 1998 to 4.0% in 2002. In addition, the criteria used for reporting ABPA in the study population were in agreement with the recently published diagnostic criteria for ABPA in CF.
CONCLUSIONS: In spite of a high frequency of atopy and a relatively humid climate in the Sydney area, Aspergillus colonisation and ABPA in CF patients was not disproportionate. Moreover, criteria for reporting of ABPA in this setting was not different from that in the Northern Hemisphere.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939251     DOI: 10.1016/j.rmed.2004.11.018

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

1.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

2.  Aspergillus fumigatus chronic colonization and lung function decline in cystic fibrosis may have a two-way relationship.

Authors:  M Noni; A Katelari; G Dimopoulos; S-E Doudounakis; C Tzoumaka-Bakoula; V Spoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-30       Impact factor: 3.267

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Domestic exposure to fungal allergenic particles determined by halogen immunoassay using subject's serum versus particles carrying three non-fungal allergens determined by allergen-specific HIA.

Authors:  J K Sercombe; D Liu-Brennan; K O McKay; B J Green; E R Tovey
Journal:  Indoor Air       Date:  2014-01-13       Impact factor: 5.770

Review 5.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  Evolution of the Immune Response to Chronic Airway Colonization with Aspergillus fumigatus Hyphae.

Authors:  Mirjam Urb; Brendan D Snarr; Gabriella Wojewodka; Mélanie Lehoux; Mark J Lee; Benjamin Ralph; Maziar Divangahi; Irah L King; Toby K McGovern; James G Martin; Richard Fraser; Danuta Radzioch; Donald C Sheppard
Journal:  Infect Immun       Date:  2015-06-29       Impact factor: 3.441

Review 7.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Kana R Jat; Dinesh K Walia; Anju Khairwa
Journal:  Cochrane Database Syst Rev       Date:  2021-09-22

8.  Detection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis.

Authors:  K de Heer; M G M Kok; N Fens; E J M Weersink; A H Zwinderman; M P C van der Schee; C E Visser; M H J van Oers; P J Sterk
Journal:  J Clin Microbiol       Date:  2015-12-16       Impact factor: 5.948

9.  Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study.

Authors:  Shawn D Aaron; Katherine L Vandemheen; Andreas Freitag; Linda Pedder; William Cameron; Annick Lavoie; Nigel Paterson; Pearce Wilcox; Harvey Rabin; Elizabeth Tullis; Nancy Morrison; Felix Ratjen
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

Review 10.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Kana R Jat; Dinesh K Walia; Anju Khairwa
Journal:  Cochrane Database Syst Rev       Date:  2018-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.